Phibro Animal Health Corporation Launches Companywide Sustainable Solutions Platform; Introduces VERRATAIN™ Verified Sustainability Solutions Through Strategic VAXA Technologies Partnership Phibro Animal Health Corporation announced the launch of its new Sustainable Solutions Platform (SSP), a companywide initiative designed to help animal protein,…
SK Capital Partners Completes Sale of Noramco, Extractas Biosciences, and Purisys to Siegfried Holding AG Affiliates of funds advised by SK Capital Partners, LP a private investment firm focused on the life sciences, specialty materials, and ingredients sectors announced today…
ProNatural Brands Announces Strong Growth, Amazon Expansion, and Accelerating Consumer Demand for Natural Cleaning Solutions ProNatural Brands announced continued strong growth and expanding market momentum as demand rises for safer, more sustainable cleaning and disinfecting solutions. Founded in 2012, ProNatural…
Availity’s Inaugural Abrasion Index Reveals Where Payer-Provider Friction Hits Healthcare Hardest Availity®, the nation’s largest health information network, today released its first annual Availity Abrasion Index, a research-informed report that measures where administrative friction between health plans and providers is highest…
Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis Organon a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, today announced…
Sutter Health Expands Use of Wearable Ultrasound Tech Across Additional Bay Area Hospitals to Advance Sepsis Care Sutter Health is expanding the use of FloPatch, the first wireless, wearable Doppler ultrasound device, across three additional Northern California hospitals: Sutter Solano…
Emalex Receives U.S. Patent for Orally Disintegrating Ecopipam Formulation Emalex Biosciences announced that the U.S. Patent and Trademark Office issued a patent covering an orally disintegrating tablet (ODT) formulation of ecopipam, an investigational D1 receptor antagonist in development for the…
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC Kardigan™, a clinical-stage precision therapeutics company developing medicines that target the root cause of specific cardiovascular diseases…
Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update Alpha Cognition Inc. a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025,…
Turn Therapeutics Secures Up to $25 Million in Financing From Avenue Capital Group Turn Therapeutics, Inc. a clinical-stage dermatology company developing novel therapies for inflammatory skin diseases, today announced it has entered into a growth capital loan facility with Avenue…
Almirall’s 17th Skin Academy Highlights Scientific Advances in Inflammatory Skin Diseases and Skin Cancer, Patient-Reported Outcomes, and Holistic Care in Medical Dermatology Almirall, a global biopharmaceutical company dedicated to medical dermatology, this weekend hosted the 17th edition of Skin Academy,…
Ionis announces zilganersen New Drug Application for Alexander disease (AxD) accepted by FDA for Priority Review Ionis Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for zilganersen, an…